Search results
Added:
1 year ago
Source:
Radcliffe CVRM
A recent study published in Circulation: Heart Failure1 has found that multimorbidity, the presence of two or more chronic health conditions, substantially increases the risk of mortality in patients with heart failure who have mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).The study analyzed data from two major heart failure trials: TOPCAT-Americas (Treatment of Preserved Cardiac…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more
Added:
8 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
A new pooled analysis suggests that measures of abdominal adiposity, such as waist-to-height ratio, are better predictors of clinical outcomes than body mass index (BMI) alone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Obesity is highly prevalent in this patient population and is linked to an increased risk of mortality and disability.This…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
Worsening kidney function is a known prognostic factor in heart failure with reduced ejection fraction (HFrEF), but a new analysis suggests this decline accelerates up to a year before a major heart failure (HF) event. The study examined data from two clinical trials, EPHESUS and EMPHASIS-HF, and the real-world BARCELONA cohort.¹This post-hoc analysis assessed longitudinal changes in estimated…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from…
View more
Added:
1 year ago
Source:
ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryA new analysis sheds light on the timing of protection offered by SGLT2 inhibitors. Researchers conducted a cross-trial analysis using individual participant data from four large-scale randomized clinical trials: CANVAS (type 2 diabetes with high atherosclerotic risk, NCT01032629), CREDENCE (diabetic kidney disease, NCT02065791), DAPA-HF (heart…
View more